Stock CPH CIPHER PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Cipher Pharmaceuticals Inc.

Equities

CPH

CA17253X1050

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
8.68 CAD +1.17% Intraday chart for Cipher Pharmaceuticals Inc. +2.00% +56.68%
Mar. 15 Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024
Mar. 14 Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023. CI

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company appears to be poorly valued given its net asset value.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CIPHER PHARMACEUTICALS INC. Stock Cipher Pharmaceuticals Inc.
+56.68% 150M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CPH Stock
  4. Ratings Cipher Pharmaceuticals Inc.